Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q4 FY25 Earnings Presentation
26 slides from Dishman Carbogen Amcis's earnings presentation, May 22, 2025
Slide 1: Cover letter to stock exchanges
22ND May, 2025 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, “Exchange Plaza”, C-1, Block G, Mumbai – 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref.: Scrip Code No.
Slide 2: Investor Presentation Quarter ended March 31, 2025
Investor Presentation Quarter ended March 31, 2025
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
DISHMAN IN A NUTSHELL 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIs in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Historical Performance at a Glance
HISTORICAL PERFORMANCE AT A GLANCE Revenue from Operations (₹ mn) EBITDA (₹ mn) and EBITDA % Cash Profit (₹ mn) 26,158 27,115 EBITDA EBITDA % 4,087 24,129 21,407 3,374 3,260 3,202 20,436 19,120 4,976 4,719 3,039 3,902 4,142 4,085 2,538 2,744 18.2% 17.2% 15.6% 17.4% 24.3% 14.3% FY20 FY21 FY22 FY23 FY
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview
Slide 7: Quarter Highlights
QUARTER HIGHLIGHTS
Slide 8: Q4 FY25 Result Highlights
Q4 FY25 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN 21.4% 15.2% 6,547 7,163 1534 996 Q4FY24 Q4FY25 Q4FY24^ Q4FY25* CASH PAT (₹ mn) & CASH EPS (₹) 6.9 4.8 1,083 752 Q4FY24^ Q4FY25* Cash PAT = Adjusted PAT + (Depreciation - additional goodwill amortization) Adjusted PAT = Adjust
Slide 9: FY25 Result Highlights
FY25 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN 17.4% 15.6% 26,158 27,115 4,719 4,085 FY24 FY25 FY24^ FY25* CASH PAT (₹ mn) & CASH EPS (₹) 19.4 20.5 3,039 3,202 FY24^ FY25* Cash PAT = Adjusted PAT + (Depreciation - additional goodwill amortization) Adjusted PAT = Adjusted PBT
Slide 10: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q4 FY25 Q4 FY24 YoY % FY25 FY24 YoY % Income from Operations (Net) 7,163.4 6,547.1 9.4% 27,115.0 26,157.7 3.7% COGS 1,459.1 1,814.1 -10.5% 5,016.5 5,971.9 -16.0% Employee Expenses 3,249.4 3,207.7 1.3% 12,935.7 12,081.6 7.1% Other Expenses 920.7 891.2 3.3
Slide 11: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET Particulars (₹ mn) Mar-25 Mar-24 Particulars (₹ mn) Mar-25 Mar-24 Equity Share Capital 313.6 313.6 Property, plant and equipment 26,838.6 24,590.9 Capital Work in Progress 2,516.9 5,008.3 Other Equity 58,001.6 55,961.4 Right to use Lease Assets 2,355.3 2,720.8 Total - Shar
Slide 12: Revenue Breakup Analysis
REVENUE BREAKUP ANALYSIS Revenue (₹ mn) Q4 FY25 Q4 FY24 % Change FY25 FY24 % Change CARBOGEN AMCIS - Contract Research & 4,889 4,490 8.9% 20,034 19,530 2.6% Manufacturing Services1 CARBOGEN AMCIS- Cholesterol & Vit D 1,211 912 32.8% 3,054 3,321 -8.04% Analogues2 DCAL India - NCE APIs & Intermediates
Slide 13: Revenue Break-up
REVENUE BREAK-UP Total Operating Revenue – Q4 FY25 Total Operating Revenue – FY25 CARBOGEN AMCIS - Contract Research & Manufacturing Services 11.2% 10.7% 3.6% 4.2% CARBOGEN AMCIS - 11.3% 16.9% Cholesterol & Vit D Analogues Q4FY25 FY25 DCAL India - NCE APIs & Intermediates 68.3% 73.9% DCAL India - Qu
Slide 14: Margin Analysis
MARGIN ANALYSIS Adjusted EBITDA Margin %* Q4 FY25 Q4 FY24 FY25 FY24 CARBOGEN AMCIS - Contract Research & 25.0% 15.6% 19.7% 17.7% Manufacturing Services1# CARBOGEN AMCIS- Cholesterol & Vit D 12.3% 25.3% 10.3% 17.8% Analogues2 DCAL India - NCE APIs & Intermediates3 17.3% 5.2% 13.1% 0.0% DCAL India - Q
Slide 15: Q4FY25 Result Highlights
Q4FY25 RESULT HIGHLIGHTS Net Revenue at Rs 7,163 mn in Q4 FY25 up by 9.4% YoY mainly due to increase in development revenue in CARBOGEN AMCIS AG and cholesterol revenue in CARBOGEN AMCIS BV. Carbogen Amcis AG – CRAMS revenue increased by 8.9% YoY in Q4 FY25 primarily due to higher share of developme
Slide 16: Company Overview
COMPANY OVERVIEW
Slide 17: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 18: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 19: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: Superior Chemistry Skills & Capabilities USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA, NMPA 28 dedicated R&D labs with multiple shift R&D CARBOGEN AMCIS BV., Veenendaal, The CARBOGEN AMCIS operations, including HIPO lab
Slide 20: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 21: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES ▪ Focus is on supporting the development process from bench to market ▪ Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 22: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 23: Industry Overview
INDUSTRY OVERVIEW
Slide 24: Expected Global Spending by Therapy Areas in 2028
EXPECTED GLOBAL SPENDING BY THERAPY AREAS IN 2028 Oncology & Obesity expected to lead growth 5-Yr CAGR 2024-2028 Oncology 440 14-17% Immunology 192 2-5% Top 20 Therapy Areas (US$ bn) - 2028 Diabetes 184 3-6% Cardiovascular 126 2-5% CNS 103 6-9% Respiratory 99 3-6% Mental health 81 9-12% Infectious d
Slide 25: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Specialty medicines will represent about 43% of global spending in 2028 and 55% of total spending in developed markets 55% 50% 43% 43% 40% 41% 35% 36% 31% 29% 23% 24% 13% 13% 10% 8% 2013 2018 2023 2028 Pharmerging Other Developed Global 10 Developed Source: IQVIA Ins
Slide 26: For Further Queries
FOR FURTHER QUERIES Mr. Harshil Dalal Dishman Carbogen Amcis Ltd Global CFO Dishman Corporate House Email: harshil.dalal@dishmangroup.com Iscon-Bopal Road, Ambli Ahmedabad - 380058 Gujarat, Arpit Mundra | Krishna Patel India Ernst & Young LLP www.imdcal.com Email: arpit.mundra@in.ey.com krishna.pate
Dishman Carbogen Amcis — Q4 FY25 Earnings Presentation on 6ix